TRIAL DETAIL

Ipilimumab and Imatinib Mesylate in Advanced Cancer

Drug:
Trial Name:
Ipilimumab and Imatinib Mesylate in Advanced Cancer
NCT#:
Conditions:
Advanced Cancer
Status:
Recruiting
Phase:
1
Start Date 02/01/2013
Age of Trial (yrs) 6.6
Treatment Phase:
Gleevec-resistant
Drug Category:
KIT/PDGFRA inhibitor + CTLA4 inhibitor
Strategy:
Block KIT + Stimulate the immune system
Trial Type:
Specifically GIST plus other cancers
Other Protocol IDs:
2012-0784
Sponsor:
M.D. Anderson Cancer Center
Patient Contact:
Contact: David S. Hong, MD 713-563-1930
Contact email:
Contact Phone:
Randomized:
IV or Oral:
Oral Intravenous
Trial Notes:
Inclusion criteria state: "For dose escalation study, patients must have histological confirmation of solid tumors that is metastatic or unresectable. For expansion cohorts, patients must have metastatic or unresectable GIST, melanoma, or uncategorized tumors that are positive for c-KIT mutations. KIT positive tumors will be confirmed in original biopsied tumors and biopsied tumors acquired during this study."

Trial Links

Trial Results

Drug Information

Trial Sites

Name
Address
City
State
Zip
Country
1505 Holcombe Blvd.
Houston
TX
77030
USA